©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Nov 14, 2014; 20(42): 15564-15579
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15564
Published online Nov 14, 2014. doi: 10.3748/wjg.v20.i42.15564
Table 1 Rationale for patient selection for neoadjuvant therapy in pancreatic cancer
| Rationale in support of neoadjuvant therapy |
| Increasing the likelihood of margin-negative resection[4,20-25] |
| Increasing the likelihood of completion of multimodality therapy[5,26-29] |
| Increasing efficacy of radiotherapy[4,24] |
| Minimizing pancreatic leak (without increasing complications)[19,30-34] |
| Determination of indeterminant lesions[29,35] |
| Declaration of distant metastases[4,29] |
| Decreasing “open-and-close” rates[19] |
| Allowing a patient’s functional status to declare itself[36] |
| Improved cost-effectiveness[37] |
- Citation: Sutton JM, Abbott DE. Neoadjuvant therapy for pancreas cancer: Past lessons and future therapies. World J Gastroenterol 2014; 20(42): 15564-15579
- URL: https://www.wjgnet.com/1007-9327/full/v20/i42/15564.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i42.15564